Antiviral Drugs for EBV

Epstein–Barr virus (EBV) infects up to 95% of the adult human population, with primary infection typically occurring during childhood and usually asymptomatic. However, EBV can cause infectious mononucleosis in approximately 35–50% cases when infection occurs during adolescence and early adulthood....

Descripción completa

Detalles Bibliográficos
Autores principales: Pagano, Joseph S., Whitehurst, Christopher B., Andrei, Graciela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6025560/
https://www.ncbi.nlm.nih.gov/pubmed/29899236
http://dx.doi.org/10.3390/cancers10060197
Descripción
Sumario:Epstein–Barr virus (EBV) infects up to 95% of the adult human population, with primary infection typically occurring during childhood and usually asymptomatic. However, EBV can cause infectious mononucleosis in approximately 35–50% cases when infection occurs during adolescence and early adulthood. Epstein–Barr virus is also associated with several B-cell malignancies including Burkitt lymphoma, Hodgkin lymphoma, and post-transplant lymphoproliferative disease. A number of antiviral drugs have proven to be effective inhibitors of EBV replication, yet have resulted in limited success clinically, and none of them has been approved for treatment of EBV infections.

Ejemplares similares